ReviewCellular and molecular life sciences : CMLS2026
Epithelial-mesenchymal transition and immunosuppression: Two sides of the same coin.
Review in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Novel approaches to overcome drug resistance in breast cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition has long been studied as a physiologic process that is critical for embryonic development, wound healing, and cancer progression. Activation of the EMT program confers on cancer cells many cellular traits associated with high-grade malignancies. These include invasion, motility, the acquisition of stem cell-like features, and resistance to multiple therapies. An emerging frontier of the EMT program, is its ability to regulate the activity of immune cells within tumors and drive resistance to immune checkpoint blockade therapies. In this review, we provide an overview of the mechanistic underpinnings of EMT-driven immunosuppression on specific subsets of innate and adaptive immune cells present within primary tumors. We also provide an insight into the role of various EMT-transcription factors in regulating the expression of cancer cell-intrinsic immunosuppressive and immunoevasive factors. Additionally, we review the consequences of EMT-driven immunosuppression on distinct steps of the invasion-metastasis cascade. Finally, we summarize studies that document EMT-driven immunosuppression in multiple cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.